Human glioblastoma in mouse

Publications

The following includes selected recent publications from our lab.

Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations [Review]

Gallus M, Young JS, Cook Quackenbush S, Khasraw M, de Groot J, Okada H

Neuro Oncol. 2024 Oct 24; doi: 10.1093/neuonc/noae203. PMID: 39450490.
PubMed Link >

Monitoring Blood-Brain Barrier Opening in Rats with a Preclinical Focused Ultrasound System

Kim K, Gallus M, Xiao T, Parchure AS, Shah BR, Okada H, Diederich C, Ozhinsky E, Narsinh K

J Vis Exp. 2024 Sep 13; 211: doi: 10.3791/66793. PMID: 39345114.
PubMed Link >

Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier

Guo Y, Lee H, Kim C, Park C, Yamamichi A, Chuntova P, Gallus M, Bernabeu MO, Okada H, Jo H, Arvanitis C

Nat Commun. 2024 Sep 13; 15 (1): 8021. doi: 10.1038/s41467-024-52329-y. PMID: 39271721; PMCID: PMC11399249.
PubMed Link >

Activating the dark genome to illuminate cancer vaccine targets

Kwok DW, Okada H, Costello JF

Nat Genet. 2024 Aug 1; 56 (9): 1770-1771. doi: 10.1038/s41588-024-01850-3. PMID: 39223317; PMCID: PMC11456370.
PubMed Link >

Lessons from Post-Immunotherapy Tumor Tissues in Clinical Trials: How Can We Fuel the Tumor Microenvironment in Gliomas? [Review]

Phung LH, Nejo T, Okada H

Vaccines (Basel). 2024 Aug 1; 12 (8): 862. doi: 10.3390/vaccines12080862. PMID: 39203988; PMCID: PMC11359082.
PubMed Link >

IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma

Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H

Neuro Oncol. 2024 Aug 8; doi: 10.1093/neuonc/noae149. PMID: 39115195.
PubMed Link >

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives [Review]

Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H.

Cells. 2024 Apr 23; 13 (9): 726. doi: 10.3390/cells13090726. PMID: 38727262; PMCID: PMC11083543.
PubMed Link >

Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment

Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H

JCI Insight. 2024 Apr 8; 9 (7): e177141. doi: 10.1172/jci.insight.177141. PMID: 38386420; PMCID: PMC11128202.
PubMed Link >

Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma

Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker PB, Naik A, Shai A, Phillips JJ, Chang SM, Wiita AP, Wells JA, Costello JF, Diaz AA, Okada H

Sci Rep. 2024 Mar 16; 14 (1): 6362. doi: 10.1038/s41598-024-56684-0. PMID: 38493204; PMCID: PMC10944514.
PubMed Link >

A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas

Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H

Neuro Oncol. 2024 Feb 2; 26 (2): 335-347. doi: 10.1093/neuonc/noad185. PMID: 37758193; PMCID: PMC10836773.
PubMed Link >

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

Kwok DW, Stevers NO, Nejo T, Chen LH, Etxeberria I, Jung J, Okada K, Cove MC, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Wu SH, Ramos E, Yamamichi A, Liu J, Watchmaker P, Ogino H, Saijo A, Du A, Grishanina N, Woo J, Diaz A, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H

bioRxiv. 2023 Oct 20; doi: 10.1101/2023.10.19.563178. PMID: 37904942; PMCID: PMC10614978.
PubMed Link >

Glioma-neuronal circuit remodeling induces regional immunosuppression

Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H.

bioRxiv. 2023 Aug 6; doi: 10.1101/2023.08.04.548295. PMID: 37577659; PMCID: PMC10418167.
PubMed Link >

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma [Review]

Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H.

Cancers. 2023 Jul 22; 15 (14): 3726. doi: 10.3390/cancers15143726. PMID: 37509387; PMCID: PMC10378701.
PubMed Link >

Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma

Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H.

Curr Opin Oncol.. 2022 Nov 1; 34 (6): 661-669. doi: 10.1097/CCO.0000000000000877. PMID: 35855503; PMCID: PMC9560977.
PubMed Link >

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.

Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H. 

J Immunother Cancer.. 2022 May 1; 10 (5): e004644. doi: 10.1136/jitc-2022-004644. PMID: 35606087; PMCID: PMC9174833.
PubMed Link >